companiesCompany
Araris Biotech (Taiho)
Swiss linker-technology company (AraLinQ) acquired by Taiho for up to $1.14B; first clinical ADC ARC-02 (CD79b) dosed in June 2026.
Taiho paid $400M at closing (2025) with up to $740M in milestones. ARC-02, a CD79b-targeted MMAE ADC built on AraLinQ site-specific conjugation, entered phase 1 in non-Hodgkin lymphoma in June 2026, the first AraLinQ product in humans.